Internal medicine (Tokyo, Japan) · 2026
Immune Checkpoint Inhibitor Therapy Triggers Autoimmune Cerebellar Ataxia with Anti-P/Q-type VGCC Antibody and Anti-mGluR5 Antibodies: A Case Report.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nakamura Shuntaro, Yamada Kazuki, Yaguchi Hiroaki, Kudo Akihiko, Fujii Shintaro, Nomura Taichi, Sato Shoki, Iwanami Taishi, Kawakita Kaiki, Sato Hanko, Majima Keita, Oiwa Kei, Iwami Kosuke, Tanaka Daiki, Eguchi Katsuki, Uwatoko Hisashi, Shirai Shinichi, Takahashi-Iwata Ikuko, Matsushima Masaaki, Fukui Doppo, Furuta Megumi, Shimizu Fumitaka, Tanaka Keiko, Konno Satoshi, Yabe Ichiro
Аннотация
Autoimmune cerebellar ataxia (ACA) is an immune-mediated cerebellar syndrome that is often associated with specific autoantibodies. We report a case of a 61-year-old man with small cell lung cancer who developed subacute progressive cerebellar ataxia after durvalumab therapy. Anti-P/Q-type voltage-gated calcium channel (VGCC) and anti-metabotropic glutamate receptor 5 (mGluR5) antibodies were detected. The patient improved substantially with early immunotherapy and the discontinuation of immune checkpoint inhibitor (ICIs) therapy. In this case, anti-VGCC antibodies may have contributed to the pathophysiology. However, anti-mGluR5 antibodies were also detected. The relationship between ACA and ICIs therapy remains unclear, and additional cases are needed.